Location of Repository

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

By M. (Mieke) Kriege, A. (Agnes) Jager, A. (Antoinette) Hollestelle, P.M.J.J. (Els) Berns, J. (Jannet) Blom, M.E. (Marion) Meijer van Gelder, A.M. (Anieta) Sieuwerts, A.M.W. (Ans) van den Ouweland, J.M. (Margriet) Collée, J.R. (Judith) Kroep, J.W.M. (John W. M.) Martens, M.J. (Maartje) Hooning and C.M. (Caroline) Seynaeve


Purpose: The role of CHEK2 in DNA repair by homologous recombination suggests that CHEK2-associated breast cancer (BC) patients might be more sensitive to chemotherapy inducing double-strand DNA breaks, but results hereon are lacking. We compared the sensitivity to first-line chemotherapy and endocrine therapy between CHEK2 1100delC and non-CHEK2 metastatic breast cancer (MBC) patients. Methods: Sixty-two CHEK2 1100delC MBC patients were selected from three cohorts genotyped for CHEK2 1100delC (one non-BRCA1/2 cohort and two sporadic cohorts). Controls were 62 non-CHEK2 MBC patients, matched for age at and year of primary BC diagnosis, and year of metastatic disease. Objective response rate (complete and partial response) to, and progression-free survival (PFS) and overall survival (OS) after start of first-line chemotherapy and endocrine therapy were compared between CHEK2 and non-CHEK2 patients. Results: Median age at BC diagnosis was 46 and 51 years at MBC diagnosis. First-line chemotherapy consisted of anthracycline-based chemotherapy (n = 73), taxanes (n = 16), CMF(-like) chemotherapy (n = 33) and taxane/anthracycline regimens (n = 2). CHEK2 and non-CHEK2 patients had a comparable objective response rate (44 vs. 52 %). Also, PFS and OS after start of chemotherapy were comparable between both patient groups (hazard ratio 0.91; 95 % confidence interval 0.63–1.30 and 1.03; 95 % CI 0.71–1.49, respectively). Thirty-six CHEK2 and 32 non-CHEK2 patients received first-line endocrine therapy (mainly tamoxifen) for MBC. No significant differences were observed in objective response rate to, and PFS and OS after start of endocrine therapy. Conclusion: No differential efficacy of chemotherapy and endocrine therapy given for MBC was observed in CHEK2 versus non-CHEK2 patients

Topics: CHEK2 1100delC, Chemotherapy, Endocrine therapy, Metastatic breast cancer, Response, Survival
Year: 2015
DOI identifier: 10.1007/s00432-015-1981-7
OAI identifier: oai:repub.eur.nl:82651

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.